Statin discontinuation and management

Stopping a statin can lessen statin‑related adverse effects such as muscle aches and may modestly lower the small rise in glucose or A1c that some patients experience. However, discontinuation also removes the well‑documented protection against heart attack and stroke that statins provide. For most people at elevated cardiovascular risk—especially those with high LDL or ApoB, documented plaque, diabetes, prior cardiovascular events, or certain high‑risk ethnic groups (e.g., South Asians)—the benefit of staying on therapy outweighs the modest diabetes risk. If side effects or rising sugars are a concern, clinicians usually try to improve tolerability before stopping the drug. Options include: - Reducing the statin dose - Switching to a different statin with a lower side‑effect profile - Using alternate‑day dosing - Correcting low vitamin D levels - A short trial of CoQ10 supplementation - Adding a non‑statin LDL‑lowering agent (e.g., ezetimibe, PCSK9 inhibitor) if LDL reduction is still needed Only patients who are truly low risk and have no compelling indication for LDL lowering might be considered for deprescribing, and this should be done in partnership with a healthcare provider. In summary, a brief “break” may improve side effects and glucose control, but routine discontinuation of statins is not recommended for most patients; instead, address tolerability while maintaining cardiovascular protection.